Informations générales (source: ClinicalTrials.gov)
A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long-term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)
Interventional
Phase 3
Merck Sharp & Dohme LLC (Voir sur ClinicalTrials)
mars 2026
janvier 2034
05 août 2026
Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau
(VHL)-related tumors:
- Advanced means the cancer has spread to other parts of the body (metastatic) or
cannot be removed with surgery
- Solid tumors are cancers mostly in body organs and tissues, not in the blood or
other body liquids
- VHL-related tumors are tumors caused by VHL disease. VHL disease is passed down from
parents to children and people with VHL disease have a higher chance of getting
certain types of cancer
Researchers want to learn about the long-term effects of a trial medicine called
belzutifan. Belzutifan, also called MK-6482, is designed to block a protein that helps
tumors grow and survive. This is an extension trial, which means only people who were in
certain other belzutifan trials (called parent trials) may be able to join. The goal of
this trial is to learn how long people live after they start taking belzutifan.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Laurence ALBIGES | 06/08/2026 13:15:06 | Contacter | ||
Critères
Tous
The main inclusion criteria include but are not limited to the following:
- Participants with advanced solid tumors or von Hippel-Lindau-related neoplasms who
are participating in belzutifan-containing studies and on active treatment in a
belzutifan parent study.
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has an on-going serious adverse event in the parent study, unless no longer
hospitalized and considered clinically stable.
- Is currently on a dose interruption due to an Adverse Event (AE) in the parent
study; once treatment has been resumed in the parent study, the participant is
eligible to enroll.